<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02570724</url>
  </required_header>
  <id_info>
    <org_study_id>5204</org_study_id>
    <nct_id>NCT02570724</nct_id>
  </id_info>
  <brief_title>HES Patch Versus Blood Patch</brief_title>
  <official_title>Clinical Effect and Cerebral Vasoconstriction Induced After Epidural Blood Patch Versus Epidural Hydroxyethyl Starch Patch in Patients With Headache Due to Intracranial Hypotension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The injection of autologous blood Blood Patch (BP) into the epidural space is the standard&#xD;
      treatment for headache associated with intracranial hypotension. It provokes cerebral&#xD;
      vasoconstriction. It is cons-indicated in a number of situations (HIV positive, fever,&#xD;
      sepsis, leukemia). The purpose of this study is to evaluate another technique using a patch&#xD;
      made by injecting an epidural hydroxyethylstarch solution (HES 130, 0.4, 6%) instead of blood&#xD;
      patch. This alternative technique is simple to implement and does not have some of the&#xD;
      specific blood pressure contra-indications. The study aims at comparing the &quot;Blood Patch&quot;&#xD;
      group versus the &quot;HES Patch&quot; in terms of clinical efficacy , tolerance, satisfaction of the&#xD;
      anesthetist, ease of implementation and effect of the injection of epidural anesthesia on&#xD;
      cerebral blood flow within 24 hours.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2013</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variation of the pulsatility index (PI) of the middle cerebral artery transcranial Doppler</measure>
    <time_frame>36 hours</time_frame>
    <description>Compare the effect of epidural injection of autologous blood (Blood Patch) versus injection of a colloid (HES Voluven ®) on cerebral blood flow.&#xD;
this study aims at observing the variation of the pulsatility index (PI) of middle cerebral artery observed by a transcranial Doppler between T0 and 30 minutes after the patch is administered.&#xD;
The BP or HEA treatment will be considered equivalent if the proportion of clinical failures and side effects do not differ by more than 5%.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Intracranial Hypotension</condition>
  <arm_group>
    <arm_group_label>Blood Patch arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care arm: injection of autologous blood approximately 40 mL of blood sample into the epidural space at a rate of 1 ml / about 5 seconds.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug: injection of HES &quot; Voluven® &quot; patch arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: injection of HES &quot; Voluven® &quot; into the epidural space of 15 to 30 ml at a rate of 1 ml / about 5 seconds</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>injection of HES &quot; Voluven® &quot;</intervention_name>
    <description>Injection into the epidural space of 15 to 30 ml Voluven ® at a rate of 1 ml / about 5 seconds.</description>
    <arm_group_label>Drug: injection of HES &quot; Voluven® &quot; patch arm</arm_group_label>
    <other_name>HYDROXYETHYL STARCH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood patch</intervention_name>
    <arm_group_label>Blood Patch arm</arm_group_label>
    <other_name>injection of autologous blood</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects older than 18 years.·&#xD;
&#xD;
          -  Subjects with an intracranial hypertension syndrome secondary to an epidural, spinal&#xD;
             or lumbar puncture (and therefore presumed iatrogenic) with a sub arachnoid space or&#xD;
             subjects with intracranial hypertension syndrome of primitive origin requiring&#xD;
             treatment with epidural Patch ·&#xD;
&#xD;
          -  subjects with a temporal window of sufficient quality to carry out the transcranial&#xD;
             Doppler ·&#xD;
&#xD;
          -  Subjects haven read the informed consent, signed and dated prior to the start of any&#xD;
             proceedings related to the tial·&#xD;
&#xD;
          -  Subjects affiliated to health insurance·&#xD;
&#xD;
          -  Subjects having been informed of the results of a prior medical consultation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a cons-indication to an epidural Patch:&#xD;
&#xD;
          -  blood disorders constitutional or acquired coagulation with platelets&#xD;
&#xD;
          -  Subjects under treatment with curative doses of antiplatelet drugs or anticoagulants&#xD;
&#xD;
          -  subjects under shock and / or hypovolemia&#xD;
&#xD;
          -  subjects under generalized sepsis or at the puncture site&#xD;
&#xD;
          -  any other cons-indication to performing an epidural&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Service Anesthésie Réanimation Chirurgicale Hôpitaux Universitaires de Strasbourg, 1 avenue Molière</name>
      <address>
        <city>Strasbourg</city>
        <state>Strasbourg Cedex</state>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>September 29, 2015</study_first_submitted>
  <study_first_submitted_qc>October 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2015</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Hypotension</mesh_term>
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

